Edwards Lifesciences Corp. — Q2 2019 Form 10-Q
Business context and reporting period. The filing covers the quarter and six months ended June 30, 2019. Edwards develops and sells medical devices for structural heart disease and critical care monitoring, with product groups in TAVR, transcatheter mitral and tricuspid therapies, surgical structural heart, and critical care.
Financial performance
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Net sales | $1,086.9M | $943.7M | $2,079.9M | $1,838.5M |
| Gross profit | $782.9M | $697.5M | $1,544.1M | $1,358.7M |
| Operating income | $267.5M | $252.1M | $541.7M | $504.6M |
| Net income | $242.3M | $282.7M | $492.0M | $489.3M |
| Diluted EPS | $1.14 | $1.32 | $2.32 | $2.28 |
- Q2 sales increased 15.2% year over year; six-month sales rose 13.1%. Q2 gross margin was approximately 72.0% versus 73.9%; operating margin was approximately 24.6% versus 26.7%.
- Q2 net income declined 14.3%, despite higher operating income, primarily reflecting a prior-year tax benefit and a current-year charge mainly for inventory. Six-month net income was nearly flat.
- Q2 product sales: TAVR $677.7M (+16.0%); surgical structural heart $217.8M (+14.5%); critical care $184.4M (+9.4%); transcatheter mitral and tricuspid therapies $7.0M, up from $0.9M.
- For the six months, operating cash flow was $342.7M, versus $291.5M. Investing cash outflow was $137.8M and financing cash outflow was $187.0M. Operating cash flow benefited from improved performance and lower prior-year tax and bonus payments, partly offset by a $180.0M litigation settlement payment and higher working-capital needs.
- At June 30, cash and cash equivalents were $726.8M, short-term investments $207.5M, and long-term investments $412.9M. Long-term debt carrying value was $594.1M; the $750M revolving credit facility had no borrowings outstanding. Management said available liquidity and operating cash flow should fund requirements for the next 12 months.
Changes, outlook, and material matters
- Sales growth was led by U.S. SAPIEN 3 and SAPIEN 3 Ultra TAVR products and surgical valves, including INSPIRIS RESILIA. TAVR sales faced foreign-exchange headwinds; management cited strong therapy adoption and continued SAPIEN 3 Ultra launches.
- Edwards recorded a $46.2M Q2 cost-of-sales charge, primarily inventory write-offs tied to strategic TAVR portfolio decisions, including discontinuing the CENTERA program. Management cited this charge as a key reason for lower Q2 diluted EPS.
- A separate $24.0M charge was recorded in Q1 for acquired early-stage transcatheter intellectual property and related clinical and regulatory experience. The company acquired CASMED in April for $100.8M cash; its Q2 sales contribution was $4.8M.
- R&D spending increased, with the company investing 17.5% of six-month sales in R&D, primarily in transcatheter structural heart programs and clinical trials. No numerical full-year revenue or earnings guidance is stated in the provided filing text.
- Edwards repurchased 1.4M shares for approximately $255M during the first half; remaining repurchase authorization was reported at $1.2B. It intended to repatriate approximately $350M of foreign earnings by September 2019.
- Abbott brought U.S. and international patent-infringement actions alleging that Edwards’ PASCAL system infringes Abbott patents; preliminary injunction requests were denied in the U.S. and U.K., while proceedings elsewhere remained ongoing. Edwards also sued Abbott over MITRACLIP-related patents. The company cautioned that outcomes could materially affect results.
- Tax exposures include unresolved transfer-pricing positions and inquiries by Dominican Republic tax authorities. Management said the analysis of the latter was ongoing; the ultimate outcomes of tax examinations may differ from recorded estimates.
- Adoption of the new lease accounting standard resulted in recognition of operating-lease assets and liabilities; management reported no impact on the income statement. Disclosure controls were assessed as effective, and no material changes to risk factors were reported.
Investor verification priorities
- Track the effect of TAVR portfolio changes and inventory charges on gross margin, product launches, and future sales.
- Separate underlying growth from currency effects and the prior-year surgical sales-return reserve, which reduced 2018 U.S. surgical sales by $63.1M year to date.
- Review cash conversion and working-capital movements, including the litigation settlement payment, and monitor liquidity after acquisitions, capital spending, and share repurchases.
- Monitor Abbott patent litigation, especially potential injunctions, trial outcomes, and any financial exposure; the filing does not provide a clear estimate of possible losses.
- Assess developments in uncertain tax positions and contingent acquisition consideration, whose valuations depend on milestone and other assumptions.